LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Molecular Diagnostics Market to Reach USD 11 Billion by 2023

By LabMedica International staff writers
Posted on 31 May 2018
The global molecular diagnostics market is expected to grow at a CAGR of 8.4% from USD 7.71 billion in 2018 to USD 11.54 billion by 2023, driven by the increasing prevalence of infectious diseases and various types of cancers, rising awareness and acceptance of personalized medicine and companion diagnostics, growth of the biomarker identification market, and advancements in molecular techniques.

These are the latest findings of MarketsandMarkets (Northbrook, IL, USA), a global market research company.

Based on technology, the PCR segment is expected to account for the largest share of the molecular diagnostics market in 2018 due to the increasing use of PCR in proteomics and genomics, automation of PCR instruments, and emergence of advanced technologies such as qRT-PCR.

On the basis application, the molecular diagnostics market is expected to be dominated by the infectious diseases segment in 2018, owing to the development of advanced assays for various diseases and conditions, sharp rise in the prevalence of infectious diseases, and growing awareness about the effective use of molecular diagnostic technologies to control the occurrence and spread of infectious diseases.

Based on end-user, the hospital & academic laboratories is expected to account for the largest share of the molecular diagnostics market in 2018 primarily on account of the large number of diagnostic tests conducted in hospitals.

In 2018, North America is expected to account for the largest share of the global molecular diagnostics market, mainly due to the high prevalence of infectious diseases and cancers, presence of a highly developed healthcare system and large number of leading national clinical laboratories, easy accessibility to technologically-advanced instruments in the region, availability of government funds, and growing applications of molecular diagnostics in genetic disorders and cancer screening.

Related Links:
MarketsandMarkets


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Manual Pipetting Aid
Pipette Controllers macro

Latest Industry News

New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
31 May 2018  |   Industry

Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada
31 May 2018  |   Industry

Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial
31 May 2018  |   Industry